Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Overview of attention for article published in Journal of Clinical Oncology, May 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 44 news outlets
blogs: 16 blogs
policy: 1 policy source
twitter: 98 X users
patent: 93 patents
facebook: 13 Facebook pages

wikipedia: 10 Wikipedia pages
googleplus: 4 Google+ users
reddit: 8 Redditors
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 1571 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 107 X posts from 98 X users, with an upper bound of 656,852 followers.

2015年に言ってたのはクラシカル免疫療法のGM-CSFを対照群とした第3相。こちらは奏効期間も奏効率も圧勝していたのに。結局ペムブロリズマブに併用するとペムブロリズマブが優秀すぎてT-VECの有効性が誤差の範囲に含まれてしまうのか。ほんと、PD-1抗体はあらゆる面で強すぎ…

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Journal of Clinical Oncology https://t.co/vptqK7EU4g

RT @farmaciaclinico: Continuamos con innovación: Virus oncolíticos - Talimogén laherparepvec https://t.co/eBzReGbI4I #SANCARLOS

Continuamos con innovación: Virus oncolíticos - Talimogén laherparepvec https://t.co/eBzReGbI4I #SANCARLOS

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 103 additional X posts.